What Is Reclast Infusion? Uses, Effects, and Risks

Reclast is the brand name for zoledronic acid, a medication delivered as a once-yearly intravenous infusion to treat osteoporosis and several other bone conditions. It belongs to a class of drugs called bisphosphonates, which slow the natural breakdown of bone tissue, and it stands out from the more familiar daily or weekly oral bone pills because a single fifteen-minute drip into a vein provides a full year of protection. That convenience comes with a distinct side-effect profile and a set of precautions worth understanding before the infusion day arrives.

How Reclast Works Inside Bone

Your skeleton is constantly remodeling itself. Specialized cells called osteoclasts dissolve old bone, and other cells called osteoblasts lay down new bone in its place. In osteoporosis, the dissolving side outpaces the building side, leaving bones thinner and more fragile. Zoledronic acid, the active ingredient in Reclast, is a nitrogen-containing bisphosphonate that binds tightly to bone mineral surfaces and is taken up by osteoclasts when they begin resorbing bone. Once inside those cells, it disrupts a key enzyme they need to function, effectively putting the brakes on bone breakdown. Because the drug locks into the bone matrix and stays there for years, a single infusion keeps working long after the IV line is removed.

Who Gets Reclast and Why

The primary reason doctors prescribe Reclast is postmenopausal osteoporosis. A yearly 5 mg infusion reduces the relative risk of clinical fracture by roughly a third, and up to three years of treatment improves bone mineral density at multiple skeletal sites while lowering bone-turnover markers that signal ongoing bone loss.¹² Reclast is also approved for people who have recently suffered a low-trauma hip fracture, a group at high risk of breaking another bone within the following year. Beyond primary osteoporosis, it is used in glucocorticoid-induced osteoporosis, the bone loss that develops in people taking long-term corticosteroids for conditions like rheumatoid arthritis or severe asthma. In head-to-head comparisons with the oral bisphosphonate risedronate, zoledronic acid performs similarly at preventing new fractures in steroid-treated patients, with the added convenience of annual dosing.³

Reclast is also prescribed for Paget’s disease of bone, a condition in which bone remodeling becomes chaotic and produces weak, enlarged, or misshapen bones. And there is growing clinical interest in its off-label use for fibrous dysplasia, a rare disorder where normal bone is replaced by fibrous tissue. In a small clinical series, most patients with fibrous dysplasia treated with zoledronic acid reported partial or complete pain relief, and markers of bone breakdown dropped substantially, though the drug did not reverse the structural bone changes visible on imaging.⁴

The Flu-Like Reaction After Infusion

The most common side effect of Reclast is the acute-phase reaction, a burst of flu-like symptoms that typically starts within the first day or two after the infusion. Fever, muscle aches, joint pain, headache, and fatigue are the hallmarks. In clinical studies, characteristic symptoms showed up in more than half of participants receiving their first dose, and blood tests confirmed spikes in inflammatory markers in at least 70 percent of volunteers.⁵ The reaction is driven by a specific subset of immune cells that recognizes a metabolic byproduct of the drug and releases a wave of inflammatory signaling molecules. It is not an allergic reaction and does not mean the drug is harming you; it is your immune system responding to a chemical signal it interprets as foreign.

The good news is that the reaction is usually self-limiting, resolving within one to three days. It also tends to be milder or absent with the second and subsequent yearly infusions, because the population of immune cells responsible for the inflammatory burst is depleted after the first exposure. Over-the-counter acetaminophen or ibuprofen taken around the time of infusion can help blunt symptoms.

One factor that predicts a rougher first infusion is vitamin D status. Patients whose blood levels of 25-hydroxyvitamin D sat below 30 ng/mL before their infusion were about four times more likely to experience a significant acute-phase reaction than those with higher levels.⁶ People who had previously taken an oral bisphosphonate also seemed somewhat less prone to the reaction, though that association weakened after accounting for vitamin D levels. The practical takeaway is that having your vitamin D checked and corrected before the infusion can meaningfully reduce the odds of spending a day or two on the couch with a fever.

Kidney Safety and What to Watch For

Reclast is cleared through the kidneys, and the infusion delivers a concentrated dose of drug that passes through them within hours. That makes kidney function the most important safety checkpoint. The prescribing guidelines set a clear floor: the drug should not be given to anyone whose kidney filtration rate falls below 35 mL per minute. Adequate hydration before and after the infusion helps protect the kidneys, and many infusion centers will run a saline drip alongside the medication for exactly this reason.

The FDA has received reports of kidney problems in patients taking Reclast, including cases that required hospitalization. In an early safety review, the agency documented 24 reports of impaired kidney function or acute kidney failure following infusion; of those patients, more than half had pre-existing conditions that put their kidneys at risk or were taking other medications known to stress the kidneys.⁷ Still, kidney injury is not limited to high-risk patients. Case reports have documented dialysis-requiring kidney damage after a single Reclast infusion even in individuals with no prior kidney disease and no history of taking kidney-toxic drugs.⁸ These events are rare, but they underline why your doctor should check a basic metabolic panel before each infusion and why staying well hydrated on infusion day is not optional advice.

Calcium Drops and Mineral Balance

Because Reclast sharply slows bone resorption, less calcium flows from bone into the bloodstream in the days following the infusion. For most people, the body compensates without trouble. But if calcium or vitamin D stores are already low going in, the drop can become clinically meaningful, producing symptoms like tingling in the fingers and around the mouth, muscle cramps, and in severe cases, heart rhythm disturbances. Doctors are advised to check calcium and vitamin D levels before prescribing Reclast and to correct any deficiency first.⁹ Patients are generally told to take calcium and vitamin D supplements before and after the infusion to keep levels in a safe range.¹⁰

This is one of those areas where the pre-infusion bloodwork really matters. The infusion itself is brief, but skipping the prep can turn a routine treatment into an urgent-care visit.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a condition in which a patch of jawbone loses its blood supply and dies, leaving exposed bone that does not heal. It has been linked to bisphosphonate use, and the association tends to dominate online discussions about these drugs. But the actual risk at the doses used for osteoporosis is quite low. A literature review identified only about a dozen well-documented cases of jaw osteonecrosis linked specifically to the once-yearly 5 mg Reclast regimen. The patients who developed it typically had one or more additional risk factors: recent dental surgery, diabetes, autoimmune conditions, prior use of other bisphosphonates or corticosteroids, or medications that suppress the immune system.¹¹

The risk climbs in people receiving higher and more frequent doses of intravenous bisphosphonates for cancer treatment, where cumulative drug exposure is many times greater than in osteoporosis regimens. If you are on Reclast for osteoporosis, the most sensible precaution is to have any major dental procedures completed before starting treatment and to maintain good oral hygiene throughout. If invasive dental work becomes necessary mid-treatment, discuss the timing with both your dentist and your prescribing doctor.

Atypical Femur Fractures

A second rare but serious complication linked to long-term bisphosphonate use is atypical fracture of the femur, the long thigh bone. These fractures typically occur in the shaft or just below the hip joint, often with minimal or no trauma, and they have a distinctive pattern on imaging: a thickened outer layer of bone and a clean, horizontal break rather than the jagged fracture you would expect from a fall. Some patients report a dull ache in the thigh for weeks or months before the bone snaps. Estimated incidence sits at roughly one case per thousand patients per year of bisphosphonate treatment, and the risk appears to increase with duration of use.¹²

The irony of an anti-fracture drug potentially causing fractures is not lost on researchers. The prevailing theory is that by suppressing bone remodeling so effectively, bisphosphonates may prevent the micro-crack repair that normally keeps bone flexible, and over years, tiny stress cracks accumulate rather than being cleared. This is why treatment duration and drug holidays, discussed below, have become a central part of how doctors use these drugs.

How Long to Stay on Reclast and When to Pause

Clinical trials show that continuing Reclast beyond three years offers additional benefit, particularly for vertebral fractures, and bone density continues to improve modestly through six years of annual infusions. After six years, though, the additional gains appear minimal.² Because the drug embeds in bone and keeps working even after the last dose, a temporary pause called a drug holiday is now standard practice. The idea is to maintain fracture protection while minimizing cumulative exposure and the attendant risk of rare side effects like jaw osteonecrosis and atypical femur fractures.

Most guidelines suggest considering a drug holiday of two to three years after an initial treatment course of three to six years, depending on the patient’s fracture risk.¹³ The decision is not one-size-fits-all. A meta-analysis found that women who still have low hip bone density after initial treatment may benefit more from continuing therapy, while those whose hip density has improved can generally take a break without a meaningful rise in fracture risk.¹⁴ During a holiday, your doctor will typically monitor bone density and may restart treatment if numbers start slipping.¹⁵

Reclast Compared with Oral Bisphosphonates

The most commonly prescribed oral bisphosphonate is alendronate, a daily or weekly pill sold under the brand name Fosamax and now widely available as a generic. In a two-year head-to-head comparison, lumbar spine bone density increased by about 5.7 percent with zoledronic acid versus 3.6 percent with alendronate, and hip density improved slightly with zoledronic acid while actually dipping a fraction with the oral drug.¹⁶ The clinical difference is modest, and both drugs reduce fractures, so the choice often comes down to practical considerations.

Oral bisphosphonates have to be swallowed on an empty stomach with a full glass of water, and you must stay upright for at least thirty minutes afterward to avoid esophageal irritation. Compliance is a known weak point: many patients skip doses or stop entirely because of heartburn, difficulty remembering, or the inconvenience of the fasting window. Reclast sidesteps all of that with a single annual infusion, and it carries no gastrointestinal side effects because the drug bypasses the digestive tract entirely. For people with conditions like Barrett’s esophagus, active reflux, or difficulty swallowing, Reclast can be the better-tolerated option by a wide margin.

Reclast Compared with Denosumab

Denosumab (brand name Prolia) is the main non-bisphosphonate injectable alternative for osteoporosis. It works by a different mechanism, blocking a protein that signals osteoclasts to form and get to work. It is given as a subcutaneous injection every six months rather than an annual IV infusion. In a retrospective comparison, denosumab produced a greater increase in spine bone density at one year than zoledronic acid, though the difference at the hip was not statistically significant. Zoledronic acid came with a significantly higher incidence of flu-like symptoms, about 29 percent versus none in the denosumab group, and patient satisfaction was similar between the two.¹⁷

However, the two drugs behave very differently when you stop them. Zoledronic acid lingers in bone for years, so its effects taper slowly after the last dose. Denosumab’s effects reverse rapidly once the injections stop, and bone density can drop sharply within months of discontinuation, sometimes accompanied by a rebound increase in vertebral fractures. Patients who stop denosumab are generally transitioned to a bisphosphonate to prevent that rebound. This makes the exit strategy a serious part of any conversation about choosing between the two, especially for younger patients who may face decades of treatment decisions.

Cost and Access

Reclast is typically administered in a hospital outpatient center, an infusion suite, or sometimes a doctor’s office. The cost includes the drug itself plus the facility and administration fees. In the United States, many insurance plans and Medicare Part B cover the infusion for patients with a qualifying diagnosis, though out-of-pocket costs vary depending on coverage. From a health-system perspective, bisphosphonates as a class are cost-savers because fractures are expensive: a cost analysis estimated annual net savings on the order of several billion dollars when osteoporotic fractures are prevented through bisphosphonate treatment, compared with the smaller savings achieved by biologic alternatives like denosumab.¹⁸ Generic intravenous zoledronic acid is now available in many markets, which has brought the drug cost down considerably from its early years on patent.

Preparing for Your Infusion

If you and your doctor decide Reclast is the right choice, there is a short checklist of things that should happen before infusion day. Blood tests for kidney function, calcium, and vitamin D are standard. Any calcium or vitamin D deficiency needs to be corrected first, because the drug will push these values lower in the short term. You will be asked to drink plenty of water in the hours before and after the infusion, and the infusion itself should run over at least fifteen minutes; faster rates have been associated with more kidney stress. Having acetaminophen on hand for the first day or two is practical planning, not pessimism.

If you have dental work pending, get it done in advance. Let your dentist know you are starting a bisphosphonate. And if you experience unexplained thigh or groin pain at any point during treatment, bring it up with your doctor rather than waiting for the next annual visit, because early imaging can catch a stress reaction before it becomes a complete fracture.

Who Should Not Receive Reclast

Reclast is contraindicated in people with kidney impairment below the filtration threshold, uncorrected low calcium, or a known allergy to zoledronic acid or any component of the infusion solution. It should not be used during pregnancy. Patients who are already receiving zoledronic acid at higher doses for cancer-related bone disease should not also receive Reclast, because the active ingredient is the same and the cumulative dose would be excessive. People with conditions that affect mineral metabolism, such as hypoparathyroidism or malabsorption syndromes, need especially careful monitoring if the drug is used at all.

For patients who cannot tolerate bisphosphonates or who have contraindications, alternatives exist. Denosumab, as noted above, works by a different pathway. Romosozumab is a newer bone-building agent that works by stimulating osteoblasts rather than slowing osteoclasts, though it carries its own cardiovascular safety considerations. Teriparatide, a synthetic form of parathyroid hormone, is another bone-building option typically reserved for severe osteoporosis. The field has moved well past a one-drug-fits-all approach, and treatment choices increasingly factor in not just efficacy but how the drug behaves when you eventually stop it.